HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a $14 price target.
August 01, 2024 | 10:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Ocular Therapeutix and maintained a $14 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $14 price target by HC Wainwright & Co. suggests strong confidence in Ocular Therapeutix's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100